Eli Lilly's stock surged 10.12% during intraday trading on Wednesday, marking a significant upward movement for the pharmaceutical giant.
The sharp rise follows the company's release of fourth-quarter 2025 financial results that substantially exceeded analyst expectations, with adjusted earnings per share of $7.54 beating estimates of $6.67 and revenue of $19.29 billion surpassing the $17.96 billion consensus.
Investors responded enthusiastically to Eli Lilly's optimistic 2026 guidance, which projects adjusted EPS of $33.50 to $35.00 and revenue of $80 billion to $83 billion, both above market forecasts, driven by soaring demand for weight-loss medications Zepbound and Mounjaro.